Shopping Cart
Remove All
Your shopping cart is currently empty
Cilostazol (OPC 21) is a Phosphodiesterase 3 Inhibitor. The mechanism of action of cilostazol is as a Phosphodiesterase 3 Inhibitor.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $37 | In Stock | In Stock | |
| 50 mg | $53 | In Stock | In Stock | |
| 100 mg | $77 | In Stock | In Stock | |
| 500 mg | $139 | In Stock | In Stock | |
| 1 g | $179 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $57 | In Stock | In Stock |
| Description | Cilostazol (OPC 21) is a Phosphodiesterase 3 Inhibitor. The mechanism of action of cilostazol is as a Phosphodiesterase 3 Inhibitor. |
| Targets&IC50 | PDE3:0.2 μM |
| In vivo | Cilostazol induces relaxation of vascular smooth muscle and causes vasodilation. It inhibits the expression of monocyte chemotactic protein-1 (MCP-1) induced by cytokines. Additionally, Cilostazol reduces plasma triglycerides and increases high-density lipoprotein (HDL) levels. The vasodilatory and antithrombotic effects of Cilostazol are primarily due to the inhibition of phosphodiesterase 3 (PDE3) and the subsequent elevation of intracellular cyclic adenosine monophosphate (cAMP) levels. It also inhibits platelet aggregation and adenosine uptake. |
| Synonyms | OPC 21, OPC 13013 |
| Molecular Weight | 369.46 |
| Formula | C20H27N5O2 |
| Cas No. | 73963-72-1 |
| Smiles | C(CCCOC=1C=C2C(=CC1)NC(=O)CC2)C=3N(N=NN3)C4CCCCC4 |
| Relative Density. | 1.34 g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 15 mg/mL (40.6 mM), Sonication is recommended. Ethanol: 3.7 mg/mL (10.01 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 1.5 mg/mL (4.06 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.